| Literature DB >> 35010428 |
Yong Chen1, Chunlin Ma1, Junmin Wang1, Ying Gu2, Yan Gao3.
Abstract
Blood flow restriction training (BFRT) is a new method for promoting muscle growth and improving muscle function, even with relatively low-intensity exercise. BFRT on patients with obesity has not been extensively studied. This study aimed to analyze the effects of cycling at 40% of maximum oxygen uptake (VO2max) combined with BFRT on body composition and serum biomarkers among college students with obesity. This pilot study included thirty-seven male college students with obesity aged 18-22 years (experimental group (EG): n = 18; control group (CG): n = 19). The EG conducted 40% VO2max cycling combined with BFRT activities and the CG conducted 40% VO2max cycling without BFRT two times per week for 12 weeks. Our results showed that in EG, there were significant differences in weight, thigh skinfold thickness (TS), waist circumference, abdominal skinfold thickness, fat mass, body fat percentage, body mass index and glucose (GLU), total cholesterol (TC), triglyceride, low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) levels before and after the experiment (p < 0.05, p < 0.01, and p < 0.001). After the experiment, TS, GLU, TC, HDL-C, and LDL-C in EG were significantly different than those of the CG (p < 0.05, p < 0.01, and p < 0.001). Together, our results demonstrate that cycling at 40% VO2max combined with BFRT may improve body composition and blood lipid profile of male college students with obesity. Our findings have important implications for those who cannot perform moderate- and high-intensity exercises.Entities:
Keywords: 40% of maximum oxygen uptake; blood flow restriction training; body composition; cycling; male college students; obesity; serum biomarkers
Mesh:
Substances:
Year: 2021 PMID: 35010428 PMCID: PMC8750492 DOI: 10.3390/ijerph19010168
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Participants’ physical characteristics and homogeneity test for physical characteristics.
| Variable | EG ( | CG ( | Levene’s Test | |||
|---|---|---|---|---|---|---|
| (M ± SD) | F |
|
|
| ||
| Age (years) | 20.3 ± 1.07 | 20.1 ± 1.08 | 0.155 | 0.696 | 0.636 | 0.529 |
| Height (cm) | 171.6 ± 3.95 | 170.2 ± 3.84 | 0.000 | 0.984 | 1.100 | 0.278 |
| Weight (Kg) | 88.7 ± 5.06 | 87.7 ± 4.60 | 0.678 | 0.416 | 0.645 | 0.523 |
| % BF (%) | 28.7 ± 1.18 | 28.9 ± 1.29 | 0.401 | 0.531 | −0.319 | 0.752 |
| BMI (Kg/m2) | 30.1 ± 0.95 | 30.3 ± 1.08 | 0.538 | 0.468 | −0.474 | 0.639 |
EG: experimental group; CG: control group; M: mean; SD: standard deviation; % BF: body fat percentage; BMI: body mass index.
Figure 1Study Procedures (HT, height; WT, weight; TCi, thigh circumference; TS, thigh skin fold thickness; WC, waist circumference; AS, abdominal skinfold thickness; FFM, fat-free mass, FM, fat mass; % BF, body fat percentage; BMI, body mass index; GLU, glucose; TC, Total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, Low-density lipoprotein cholesterol).
The influence of different interventions on body composition (two-way ANOVA).
| Item | Between-Subject (Group) | Within-Subject (Time) | Interaction (Group × Time) | |||
|---|---|---|---|---|---|---|
| F (1, 35) | Partial η2 | F (1, 35) | Partial η2 | F (1, 35) | Partial η2 | |
| WT (kg) | 0.000 | 0.000 | 43.627 * | 0.555 | 9.713 * | 0.271 |
| TCi (cm) | 0.089 | 0.003 | 7.247 * | 0.172 | 0.133 | 0.004 |
| TS (mm) | 3.818 | 0.098 | 15.419 * | 0.555 | 0.275 | 0.073 |
| WC (cm) | 0.349 | 0.010 | 7.118 * | 0.169 | 4.327 * | 0.110 |
| AS (mm) | 1.041 | 0.029 | 5.096 * | 0.127 | 2.789 | 0.074 |
| FFM (kg) | 0.185 | 0.005 | 6.270 * | 0.152 | 0.691 | 0.019 |
| FM (kg) | 0.346 | 0.010 | 22.179 * | 0.388 | 8.434 * | 0.194 |
| % BF (%) | 1.904 | 0.030 | 11.750 * | 0.251 | 12.613 * | 0.265 |
| BMI (kg/m2) | 2.098 | 0.057 | 9.844 * | 0.220 | 2.059 | 0.056 |
WT, weight; TCi, thigh circumference; TS, thigh skin fold thickness; WC, waist circumference; AS, abdominal skinfold thickness; FFM, fat-free mass, FM, fat mass; % BF, body fat percentage; BMI, body mass index; * p < 0.05.
Changes of body composition of experimental and control groups before and after 12 weeks (t-test).
| Body Composition Components | Group | Pre | Post | Pre-Post Difference |
|
|---|---|---|---|---|---|
| (M ± SD) | |||||
| WT | EG ( | 88.7 ± 5.06 | 85.5 ± 4.85 | 3.22 ± 5.46 | 2.50 * |
| CG ( | 87.7 ± 4.60 | 86.5 ± 4.97 | 1.15 ± 2.68 | 1.88 | |
| TCi | EG ( | 60.6 ± 3.66 | 58.7 ± 3.74 | 1.94 ± 4.40 | 1.86 |
| CG ( | 60.1 ± 2.72 | 58.6 ± 3.64 | 1.47 ± 3.25 | 2.00 | |
| TS | EG ( | 27.8 ± 2.09 | 26.3 ± 2.25 | 1.56 ± 1.85 | 3.56 ** |
| CG ( | 28.5 ± 1.83 | 27.9 ± 1.89 | 0.63 ± 1.53 | 1.80 | |
| WC | EG ( | 97.6 ± 3.28 | 96.5 ± 2.90 | 1.11 ± 1.85 | 2.54 * |
| CG ( | 96.4 ± 3.70 | 96.3 ± 3.94 | 0.14 ± 0.82 | 0.73 | |
| AS | EG ( | 54.9 ± 3.84 | 54.4 ± 3.60 | 0.53 ± 0.96 | 2.33 * |
| CG ( | 55.9 ± 3.99 | 55.9 ± 3.57 | 0.08 ± 0.65 | 0.53 | |
| FFM | EG ( | 63.2 ± 3.14 | 61.4 ± 3.88 | 1.74 ± 4.09 | 1.81 |
| CG ( | 62.3 ± 2.85 | 61.5 ± 3.24 | 0.87 ± 1.94 | 1.96 | |
| FM | EG ( | 25.5 ± 2.24 | 24.0 ± 1.63 | 1.47 ± 1.46 | 4.27 ** |
| CG ( | 25.3 ± 2.14 | 25.0 ± 2.11 | 0.35 ± 0.82 | 1.86 | |
| % BF | EG ( | 28.7 ± 1.18 | 28.1 ± 1.38 | 0.59 ± 0.59 | 4.25 ** |
| CG ( | 28.9 ± 1.29 | 28.9 ± 1.28 | 0.01 ± 0.43 | −0.11 | |
| BMI | EG ( | 30.1 ± 0.951 | 29.0 ± 1.45 | 1.06 ± 1.79 | 2.51 * |
| CG ( | 30.3 ± 1.08 | 29.9 ± 1.44 | 0.40 ± 0.92 | 1.88 | |
EG: Experimental Group; CG: Control Group; WT, weight; TCi, thigh circumference; TS, thigh skin fold thickness; WC, waist circumference; AS, abdominal skinfold thickness; FFM, fat-free mass, FM, fat mass; % BF, body fat percentage; BMI, body mass index; * p < 0.05; ** p < 0.01.
The influence of different interventions on serum biomarkers (two-way ANOVA).
| Item | Between-Subject (Group) | Within-Subject (Time) | Interaction (Group × Time) | |||
|---|---|---|---|---|---|---|
| F (1, 35) | Partial η2 | F (1, 35) | Partial η2 | F (1, 35) | Partial η2 | |
| GLU (mmol/L) | 5.282 * | 0.131 | 100.003 * | 0.741 | 41.002 * | 0.539 |
| TC (mmol/L) | 10.296 * | 0.227 | 77.642 * | 0.689 | 48.621 * | 0.581 |
| TG (mmol/L) | 0.166 | 0.005 | 9.530 * | 0.214 | 2.498 | 0.067 |
| HDL-C (mmol/L) | 0.925 | 0.026 | 16.049 * | 0.314 | 21.881 * | 0.385 |
| LDL-C (mmol/L) | 3.584 | 0.093 | 239.654 * | 0.873 | 148.409 * | 0.809 |
GLU, glucose; TC, Total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, Low-density lipoprotein cholesterol; * p <0.05.
Changes of serum biomarkers of experimental and control groups before and after 12 weeks (t-test).
| Serum Biomarkers | Group | Pre | Post | Pre-Post Difference |
|
|---|---|---|---|---|---|
| (M ± SD) | |||||
| GLU | EG ( | 5.36 ± 0.30 | 4.92 ± 0.29 | 0.43 ± 0.17 | 11.00 *** |
| CG ( | 5.39 ± 0.25 | 5.29 ± 0.26 | 0.10 ± 0.16 | 2.68 * | |
| TC | EG ( | 4.99 ± 0.20 | 4.59 ± 0.27 | 0.41 ± 0.21 | 8.38 *** |
| CG ( | 5.01 ± 0.17 | 4.96 ± 0.16 | 0.05 ± 0.09 | 2.36 * | |
| TG | EG ( | 1.27 ± 0.19 | 1.20 ± 0.16 | 0.08 ± 0.11 | 2.75 * |
| CG ( | 1.28 ± 0.25 | 1.25 ± 0.23 | 0.02 ± 0.079 | 1.34 | |
| HDL-C | EG ( | 1.50 ± 0.22 | 1.71 ± 0.17 | 0.14 ± 0.13 | −4.36 *** |
| CG ( | 1.51 ± 0.20 | 1.50 ± 0.20 | 0.01 ± 0.03 | 1.40 | |
| LDL-C | EG ( | 2.55 ± 0.56 | 1.98 ± 0.54 | 0.57 ± 0.11 | 2.08 *** |
| CG ( | 2.61 ± 0.43 | 2.55 ± 0.49 | 0.07 ± 0.13 | 2.22 * | |
EG: Experimental Group; CG: Control Group; GLU, glucose; TC, Total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, Low-density lipoprotein cholesterol; * p < 0.05; *** p < 0.001.